title: Recurrent Trichosporon asahii glossitis: a case report.
abstract: OBJECTIVE
  This case report aims at describing an infection of the tongue as a manifestation of a Trichosporon asahii infection, its association with bronchial asthma and steroid administration, and to present a review of the literature pertaining to its antifungal susceptibility profile.
  
  
  BACKGROUND
  Trichosporon asahii has been reported to be associated with a wide spectrum of clinical manifestations, ranging from superficial infection to severe disseminated diseases, particularly in immunocompromised patients.
  
  
  METHODS
  A 36-year-old male asthmatic patient with recurrent glossitis presented with a chief complaint of burning sensation and two red areas on the dorsum of the tongue of three months duration. The glossitis was associated with Trichosporon asahii, which had a reduced susceptibility to some azole antifungal agents.
  
  
  CONCLUSIONS
  Trichosporon asahii is an emerging fungal pathogen which may cause a wide range of clinical manifestations. More reports on its various clinical presentations in the oral environment need to be made available in the literature. To date there is a paucity of data on its prevalence, pathogenesis, and antifungal resistance mechanism.
authors.affiliation: School of Dental Sciences of Universiti Sains Malaysia in Kota Bharu, KN, Malaysia. banshareef@kb.usm.my
authors.forename: Ban Tawfeek
authors.initials: BT
authors.lastname: Shareef
authors.forename: Azian
authors.initials: A
authors.lastname: Harun
authors.forename: Yusof
authors.initials: Y
authors.lastname: Roziawati
authors.forename: Ismail Shaiful
authors.initials: IS
authors.lastname: Bahari
authors.forename: Zakuan Zainy
authors.initials: ZZ
authors.lastname: Deris
authors.forename: Manickam
authors.initials: M
authors.lastname: Ravichandran
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects; D019819:Budesonide / Q000008:administration & dosage / Q000009:adverse effects; D025141:Drug Resistance, Fungal; D005928:Glossitis / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D009181:Mycoses / Q000188:drug therapy / Q000382:microbiology*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use; D012008:Recurrence; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use; D014250:Trichosporon; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D001993:Bronchodilator Agents; D011743:Pyrimidines; D014230:Triazoles; D019819:Budesonide; D065819:Voriconazole